Thomas J. Herzfeld Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30	Closed	-$2K	–	331
2022 Q2	$2K	Hold	30	–	–	﹤0.01%	300
2022 Q1	$2K	Hold	30	–	–	﹤0.01%	312
2021 Q4	$3K	Hold	30	–	–	﹤0.01%	331
2021 Q3	$3K	Hold	30	–	–	﹤0.01%	315
2021 Q2	$3K	Buy	30 +8	+36%	+$833	﹤0.01%	326
2021 Q1	$3K	Buy	22 +1	+5%	+$136	﹤0.01%	312
2020 Q4	$3K	Buy	21 +6	+40%	+$712	﹤0.01%	273
2020 Q3	$2K	Buy	+15	New	+$1.24K	﹤0.01%	245

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Thomas J. Herzfeld Advisors's RARE Position: Q3 2022 in Review

Thomas J. Herzfeld Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 30 shares — an estimated $2K sold.

Thomas J. Herzfeld Advisors first reported a position in RARE in Q3 2020 and held it in 8 quarters. The position peaked at $3K in Q4 2021. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

Thomas J. Herzfeld Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 30 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $2K.
Thomas J. Herzfeld Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 8 quarters.
Thomas J. Herzfeld Advisors's Ultragenyx Pharmaceutical position peaked at $3K in Q4 2021.
232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.